Ignite Creation Date:
2024-05-06 @ 5:54 PM
Last Modification Date:
2024-10-26 @ 2:38 PM
Study NCT ID:
NCT05474820
Status:
COMPLETED
Last Update Posted:
2023-10-23
First Post:
2022-07-23
Brief Title:
Saliva Irisin Level is Higher and Related With Interleukin 6 in Generalized Periodontitis
Sponsor:
Istanbul Medipol University Hospital
Organization:
Istanbul Medipol University Hospital
Study Overview
Official Title:
Saliva Irisin Level is Higher and Related With Interleukin 6 in Generalized Periodontitis
Status:
COMPLETED
Status Verified Date:
2022-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Irisin is novel adipomyokine known as a mediator of physical activity that produced mainly by skeletal muscle and adipose tissues It is cleaved from the fibronectin type III domain-containing protein 5 FDNC5 which is in turn induced by peroxisome proliferator-activated receptor-ɣ co-activator 1-α PGC-1α Several studies reported that irisin is related with pathogenesis of many diseases which are known to be associated with periodontal disease such as obesity diabetes mellitus rheumatoid arthritis cardiovascular disease nonalcoholic fatty liver disease and metabolic bone diseases There are several studies those have reported that increased IL-6 levels are associated with progression and severity of periodontitis Recently it has been shown that irisin is expressed in human periodontal ligament cells hPDL dental pulp stem cells and osteoblasts Also a few studies revealed that irisin promotes growth migration and matrix formation in hPDL cells and cementoblast differentiation To the best our knowledge there s one study has been reported that the higher levels of irisin in saliva in patient with chronic periodontitis
Detailed Description:
Twenty systemically healthy subjects with healthy periodontium and 20 patients with stage III grade B generalized periodontitis were enrolled for this cross-sectional study The study was performed in accordance with the Helsinki Declaration of 1975 as revised in 2013 Before starting the informed consent was obtained from all participants which was approved by the human subjects ethics board of Istanbul Medipol Universitys Faculty of Dentistry for use and access of human subjects in researchFor all study subjects the exclusion criteria were 1 use of contraceptive drugs 2 use of antibiotics anti-inflammatory drugs or immunosuppressants in the last 3 months before the study 3 alcohol consumption 4 pregnancy or breastfeeding 5 taking drugs that could cause side effects such as gingival hypertrophy or hyperplasia and 6 any periodontal treatments in the 3 months prior to enrollment All participants were systemically healthy and non-smokers never smokersThe clinical periodontal parameters plaque index PI probing pocket depth PD gingival recession GR clinical attachment loss CAL and bleeding on probing BOP were recorded on periodontal charts in each patient For the analysis of irisin and IL-6 specific ELISA Kits Elabscience Houston Texas USA were used to determine the molecules in both serum and saliva samples in accordance with the manufacturers instructions The minimum detectable doses of irisin and IL-6 for saliva with these assay kits were 128 and 1322 pgml respectively For serum minimum detectable irisin dose was 17543 whereas IL-6 was 006 pgml All samples were run in duplicate and values have been averaged
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None